Forty Seven Raises $75m For Potential 'Universal' CD47 Cancer Therapy
This article was originally published in Scrip
Executive Summary
Forty Seven Inc. has $75m in Series A venture capital and something else that's pretty novel for a startup biotechnology company: an immuno-oncology development program that's already in the clinic with data expected later this year.
You may also be interested in...
VC Roundup: More Funds Raise Cash For Biotech; Morphic Closes $51.5m Series A
Five venture capital firms raised new funds to finance biopharma companies in June and five therapeutics developers closed early-stage funding rounds during the last week of June.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.